A Randomized, Open-label (Formerly Double-blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Everolimus (Primary) ; Lenvatinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 21 Nov 2018 Planned number of patients changed from 306 to 338.
- 28 Sep 2018 Planned End Date changed from 15 Jun 2021 to 15 Sep 2019.
- 28 Sep 2018 Planned primary completion date changed from 15 Jan 2021 to 15 Sep 2019.